Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites
- PMID: 7166180
- DOI: 10.1007/BF03189631
Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites
Abstract
A total of 16 metabolites of bromocriptine could be isolated from rat bile and incubates of rat liver cell preparations using [6-methyl-14C]bromocriptine as substrate. Separation and purification was achieved by reversed-phase liquid chromatography and preparative thin-layer chromatography in conjunction with radioactivity monitoring. Structure elucidation was based on spectroscopic data (UV, IR, NMR, EI- and FD-MS) and the results of amino acid analysis after acid hydrolysis. Based on the identified metabolites four principal transformation process could be described: -Hydrolytic cleavage of the amide bridge leading to the formation of 2-bromolysergic acid amide (3) and 2-bromolysergic acid (7). -epimerization at position 8 of the bromolysergic acid moiety to the iso-derivatives (isobromocriptine, 2-bromo-isolysergic acid (6), its amide (1), etc.) -regiospecific oxidation at position 8' in the proline fragment generating stereoisomeric 8'-hydroxy-bromocriptines (21-24) -further oxidation of the 8'-hydroxylated derivatives by either the introduction of a second hydroxy group at position 9' to give dihydroxylated derivatives (detected as conjugates with glucuronic acid: metabolites 29, 30 and 31), or the opening of the proline ring under formation of the metabolites 4 and 5 containing glutamic acid instead of proline (7', 8'-seco- 8'-carboxy-bromocriptines). It is suggested that the primary and principal metabolic attack occurs at the proline fragment of the drug. In contrast to the biotransformation of ergoline compounds, none of the bromocriptine metabolites detected showed oxidative transformations in the lysergic acid half of the molecule.
Similar articles
-
Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism.Eur J Drug Metab Pharmacokinet. 1983;8(1):51-62. doi: 10.1007/BF03189581. Eur J Drug Metab Pharmacokinet. 1983. PMID: 6861794
-
Pharmacokinetics of nisoldipine. III. Biotransformation of nisoldipine in rat, dog, monkey, and man.Arzneimittelforschung. 1988 Aug;38(8):1105-10. Arzneimittelforschung. 1988. PMID: 2973788
-
Biotransformation of hexapropymate in man. Part 2: Isolation and identification of metabolites.Pharmazie. 1984 Feb;39(2):114-7. Pharmazie. 1984. PMID: 6718477
-
Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.Arzneimittelforschung. 1982;32(9):995-1012. Arzneimittelforschung. 1982. PMID: 6756419 Review.
-
seco-1-Azacubane-2-carboxylic acid-Amide Bond Comparison to Proline.J Org Chem. 2023 Sep 15;88(18):12867-12871. doi: 10.1021/acs.joc.3c01264. Epub 2023 Aug 30. J Org Chem. 2023. PMID: 37647582 Review.
Cited by
-
Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum.Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):79-84. doi: 10.1007/BF03190071. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11112086
-
Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand.J Biol Chem. 2012 Jan 27;287(5):3510-7. doi: 10.1074/jbc.M111.317081. Epub 2011 Dec 7. J Biol Chem. 2012. PMID: 22157006 Free PMC article.
-
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.Diabetes Care. 2011 Apr;34(4):789-94. doi: 10.2337/dc11-0064. Diabetes Care. 2011. PMID: 21447659 Free PMC article. Review. No abstract available.
-
Risks for animal health related to the presence of ergot alkaloids in feed.EFSA J. 2024 Jan 23;22(1):e8496. doi: 10.2903/j.efsa.2024.8496. eCollection 2024 Jan. EFSA J. 2024. PMID: 38264299 Free PMC article.
-
Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man.Eur J Clin Pharmacol. 1984;26(4):463-70. doi: 10.1007/BF00542142. Eur J Clin Pharmacol. 1984. PMID: 6428916